Change in Vorapaxar Study

Here is a January 13 announcement from theheart.org indicating that Merck has discontinued a portion of a phase III trial of vorapaxar, an oral antiplatelet drug that blocks the thrombin membrane receptor protease activated receptor-1 (PAR-1). The study change responds to safety data involving study participants who had had a stroke. The myocardial infarction and peripheral vascular disease arms of the study are progressing.